Assignee
SILENCE THERAPEUTICS GMBH
DE·28 granted patents·22 pending applications·128 citations·filing 2014–2025
Top patents by PatentIndex Score
50 records- 0198US9695423B2Interfering RNA moleculesSILENCE THERAPEUTICS GMBH·Filed 2015·Granted Jul 4, 2017·46 cites·25 claims
- 0295US11015198B2Products and compositionsSILENCE THERAPEUTICS GMBH·Filed 2018·Granted May 25, 2021·14 cites·7 claims
- 0395US9790505B2Interfering RNA moleculesSILENCE THERAPEUTICS GMBH·Filed 2017·Granted Oct 17, 2017·10 cites·23 claims
- 0492US11499153B2Nucleic acids for inhibiting expression of LPA in a cellSILENCE THERAPEUTICS GMBH·Filed 2021·Granted Nov 15, 2022·2 cites·28 claims
- 0592US11319537B2Nucleic acids for inhibiting expression of LPA in a cellSILENCE THERAPEUTICS GMBH·Filed 2018·Granted May 3, 2022·18 cites·15 claims
- 0692US9790501B2Interfering RNA moleculesSILENCE THERAPEUTICS GMBH·Filed 2017·Granted Oct 17, 2017·6 cites·30 claims
- 0792US9758784B1Interfering RNA moleculesSILENCE THERAPEUTICS GMBH·Filed 2017·Granted Sep 12, 2017·6 cites·24 claims
- 0891US9783802B2Interfering RNA moleculesSILENCE THERAPEUTICS GMBH·Filed 2017·Granted Oct 10, 2017·5 cites·28 claims
- 0990US11174483B2Products and compositionsSILENCE THERAPEUTICS GMBH·Filed 2018·Granted Nov 16, 2021·6 cites·19 claims
- 1088US12084656B2Products and compositionsSILENCE THERAPEUTICS GMBH·Filed 2021·Granted Sep 10, 2024·1 cites·14 claims
- 1188US12054717B2Nucleic acids for inhibiting expression of LPA in a cellSILENCE THERAPEUTICS GMBH·Filed 2022·Granted Aug 6, 2024·1 cites·17 claims
- 1288US9486538B2Lipids, lipid complexes and use thereofSILENCE THERAPEUTICS GMBH·Filed 2015·Granted Nov 8, 2016·3 cites·14 claims
- 1386US10329568B2Interfering RNA moleculesSILENCE THERAPEUTICS GMBH·Filed 2018·Granted Jun 25, 2019·2 cites·24 claims
- 1486US10323246B2Interfering RNA moleculesSILENCE THERAPEUTICS GMBH·Filed 2017·Granted Jun 18, 2019·2 cites·30 claims
- 1586US10266829B2Interfering RNA moleculesSILENCE THERAPEUTICS GMBH·Filed 2018·Granted Apr 23, 2019·2 cites·23 claims
- 1684US10913945B2Nucleic acid linked to a trivalent glycoconjugateSILENCE THERAPEUTICS GMBH·Filed 2017·Granted Feb 9, 2021·2 cites·3 claims
- 1783US2025043288A1Products and compositionsSILENCE THERAPEUTICS GMBH·Filed 2024·Application pending·0 cites
- 1882US11414660B2Products and compositionsSILENCE THERAPEUTICS GMBH·Filed 2018·Granted Aug 16, 2022·2 cites·20 claims
- 1980US2024327843A1Nucleic acids for inhibiting expression of lpa in a cellSILENCE THERAPEUTICS GMBH·Filed 2024·Application pending·0 cites
- 2078US10774332B2Interfering RNA moleculesSILENCE THERAPEUTICS GMBH·Filed 2019·Granted Sep 15, 2020·0 cites·24 claims
- 2177US11578328B2Interfering RNA moleculesSILENCE THERAPEUTICS GMBH·Filed 2020·Granted Feb 14, 2023·0 cites·13 claims
- 2277US2026078372A1Nucleic acids for inhibiting expression of lpa in a cellSILENCE THERAPEUTICS GMBH·Filed 2025·Application pending·0 cites
- 2376US2024200071A1Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkagesSILENCE THERAPEUTICS GMBH·Filed 2023·Application pending·0 cites
- 2470US2025025488A1Nucleic acids for inhibiting expression of tmprss6 and iron chelatorsSILENCE THERAPEUTICS GMBH·Filed 2024·Application pending·0 cites
- 2568US11987794B2Products and compositionsSILENCE THERAPEUTICS GMBH·Filed 2022·Granted May 21, 2024·0 cites·22 claims
- 2668US11753642B2Nucleic acids for inhibiting expression of C3 in a cellSILENCE THERAPEUTICS GMBH·Filed 2022·Granted Sep 12, 2023·0 cites·29 claims
- 2764US11912993B2Nucleic acid linked to a trivalent glycoconjugateSILENCE THERAPEUTICS GMBH·Filed 2020·Granted Feb 27, 2024·0 cites·13 claims
- 2864US2023272385A1siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRANDSILENCE THERAPEUTICS GMBH·Filed 2022·Application pending·0 cites
- 2964US2017036990A1Lipids, lipid complexes and use thereofSILENCE THERAPEUTICS GMBH·Filed 2016·Application pending·0 cites
- 3063US2022002722A1Nucleic acids for inhibiting expression of lpa in a cellSILENCE THERAPEUTICS GMBH·Filed 2019·Application pending·0 cites
- 3162US2022025377A1Products and compositionsSILENCE THERAPEUTICS GMBH·Filed 2021·Application pending·0 cites
- 3262US2025163415A1Therapeutic Inhibition of LPA ExpressionSILENCE THERAPEUTICS GMBH·Filed 2023·Application pending·0 cites
- 3361US11873489B2Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkagesSILENCE THERAPEUTICS GMBH·Filed 2018·Granted Jan 16, 2024·0 cites·14 claims
- 3459US12076335B2Nucleic acids for inhibiting expression of TMPRSS6 and iron chelatorsSILENCE THERAPEUTICS GMBH·Filed 2019·Granted Sep 3, 2024·0 cites·12 claims
- 3557US2022195436A1Nucleic acids for inhibiting expression of c3 in a cellSILENCE THERAPEUTICS GMBH·Filed 2020·Application pending·0 cites
- 3655US9387262B2Coated lipid complexes and their useSILENCE THERAPEUTICS GMBH·Filed 2014·Granted Jul 12, 2016·0 cites·15 claims
- 3755US2025136977A1Nucleic acids for inhibiting expression of complement factor b (cfb) in a cellSILENCE THERAPEUTICS GMBH·Filed 2022·Application pending·0 cites
- 3854US2024240187A1Sirna targeting tmprss6 for the treatment of myeloproliferative disordersSILENCE THERAPEUTICS GMBH·Filed 2022·Application pending·0 cites
- 3953US2025230441A1Nucleic acids for inhibiting expression of MASP-2 in a cellSILENCE THERAPEUTICS GMBH·Filed 2023·Application pending·0 cites
- 4052US2014249207A1Means for inhibiting the expression of orc-1SILENCE THERAPEUTICS GMBH·Filed 2014·Application pending·0 cites
- 4152US2015337382A1Further use of protein kinase n betaSILENCE THERAPEUTICS GMBH·Filed 2015·Application pending·0 cites
- 4250US11560563B2SiRNAs with vinylphosphonate at the 5′ end of the antisense strandSILENCE THERAPEUTICS GMBH·Filed 2019·Granted Jan 24, 2023·0 cites·16 claims
- 4350US11299738B2Further novel oligonucleotide-ligand conjugatesSILENCE THERAPEUTICS GMBH·Filed 2018·Granted Apr 12, 2022·0 cites·23 claims
- 4450US2016303047A1Means for lung specific deliverySILENCE THERAPEUTICS GMBH·Filed 2014·Application pending·0 cites
- 4549US9458461B2Means for inhibiting the expression of ANG2SILENCE THERAPEUTICS GMBH·Filed 2014·Granted Oct 4, 2016·0 cites·15 claims
- 4648US2021155926A1siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDSSILENCE THERAPEUTICS GMBH·Filed 2019·Application pending·0 cites
- 4747US2022017899A1Nucleic acids for inhibiting expression of c3 in a cellSILENCE THERAPEUTICS GMBH·Filed 2019·Application pending·0 cites
- 4846US2019038557A1Means for lung specific deliverySILENCE THERAPEUTICS GMBH·Filed 2018·Application pending·0 cites
- 4946US2017296469A1Lipoplex formulations for specific delivery to vascular endotheliumSILENCE THERAPEUTICS GMBH·Filed 2017·Application pending·0 cites
- 5042US2015368650A1Use of vegfr1 as a biomarkerSILENCE THERAPEUTICS GMBH·Filed 2015·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →